Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,774 across all filing types
Latest filing 2018-03-29 Annual Report
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Annual financial report 2017
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT 2017' and contains a comprehensive table of contents covering financial statements, management reports, corporate governance, and auditor reports. It provides detailed financial performance data, strategic outlooks, and consolidated financial statements for the fiscal year. It is not an announcement of a report, but the report itself. FY 2017
2018-03-29 German
EVOTEC AG FISCAL YEAR 2017 RESULTS: LEADING EXTERNAL INNOVATION
Earnings Release Classification · 100% confidence The document is titled 'EVOTEC AG FISCAL YEAR 2017 RESULTS' and reports detailed financial performance metrics for the fiscal year ended 31 December 2017, including Group revenues, Adjusted Group EBITDA, R&D expenses, segment performance (EVT Execute and EVT Innovate), and corporate activities like acquisitions (Aptuit). It also provides a strong financial outlook for 2018 ('3X30'). This content structure—comprehensive annual financial review, segment breakdown, and forward guidance—is characteristic of a full Annual Report, which corresponds to the 10-K filing type in the US context, or the primary annual financial disclosure document globally. Although it is presented as a news release/DGAP-News, the substance is the full annual financial results, not just a brief earnings release (ER). The document length (26,593 chars) also supports it being a comprehensive report rather than a short announcement (RPA/RNS). FY 2017
2018-03-28 English
Präsentation FY 2017
Investor Presentation Classification · 96% confidence The document is titled with sections like 'Summary 2017 & Action Plan 2022', contains detailed financial tables comparing 2017 results against guidance, discusses strategic goals ('Action Plan 2022'), and includes forward-looking statements typical of corporate reporting. The content focuses on reviewing past performance (2017) and setting future outlook/guidance (2018 and 2022). This structure strongly suggests an Investor Presentation (IP) or a detailed Management Discussion and Analysis (MDA) section within a larger report. Given the format, which appears to be a slide deck or presentation summarizing performance and strategy, 'Investor Presentation' (IP) is the most appropriate classification. It is not a full 10-K, nor is it a short earnings release (ER) or a simple announcement (RPA/RNS).
2018-03-28 English
Evotec AG plans conversion into European Company (SE)
AGM Information Classification · 95% confidence The document is an 'Ad-hoc' announcement dated March 27, 2018, disclosing inside information regarding Evotec AG's plan to convert into a European Company (SE). This proposal is explicitly stated to be put to a vote at the upcoming Annual General Meeting (AGM) on June 20, 2018. Since the core subject is a major corporate action (conversion) that requires shareholder approval at the AGM, and the document is a formal announcement of this plan, it relates closely to corporate governance and shareholder meetings. However, none of the specific codes perfectly match 'Corporate Action Announcement' or 'Legal Structure Change'. Reviewing the definitions: - AGM-R: Materials shared *during* the AGM, not the announcement of a proposal for the AGM. - MANG: Not about board/management changes. - CAP: While it involves capital structure, it's primarily a legal form change requiring shareholder vote. - LTR: Not a legal proceeding. - RNS: This is a general regulatory announcement (disclosing inside information under MAR) that doesn't fit a more specific category. The content is a significant corporate governance/structural change announcement. Given the nature of the announcement—a mandatory disclosure of a significant structural change that will be voted on at the AGM—it is a regulatory filing concerning corporate structure. Since there is no specific code for 'Legal Structure Change' or 'Shareholder Vote Proposal', and it is a formal disclosure of inside information (Article 17 MAR), the most appropriate general category is Regulatory Filings (RNS). If the document were the actual proposal materials for the AGM, AGM-R would be considered, but this is the announcement *of* the proposal. Considering the options, RNS serves as the best fit for a mandatory, non-financial, non-insider trading regulatory disclosure about a major corporate action.
2018-03-27 English
EVOTEC LAUNCHES INDIGO, A UNIQUE INTEGRATED DRUG DEVELOPMENT SOLUTION FOR ACCELERATING EARLY DRUG CANDIDATES INTO THE CLINIC
Regulatory Filings Classification · 100% confidence The document is a press release dated March 26, 2018, announcing the launch of a new integrated drug development solution called INDiGO by Evotec AG. It uses keywords like "News Details," "DGAP-News," "Corporate," and includes boilerplate language about dissemination via DGAP (a service often used for regulatory news in Germany). This is not a formal SEC filing like a 10-K, nor is it a financial report (ER, IR). It is a specific announcement about a new product/service offering, which is best categorized as a general corporate announcement or news release. Since there is no specific category for 'Product Launch Announcement,' and it is a formal news release disseminated via a regulatory service (DGAP), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that don't fit elsewhere, especially when originating from a regulated news distribution system.
2018-03-26 English
EVOTEC AG TO REPORT FISCAL YEAR 2017 RESULTS ON 28 MARCH 2018
Report Publication Announcement Classification · 99% confidence The document is a news release dated March 21, 2018, announcing that EVOTEC AG will report its fiscal year 2017 results on March 28, 2018. It provides details for an upcoming conference call and webcast to discuss these results and provide an outlook for 2018. This is not the actual financial report (10-K or IR), but rather an announcement about the future release of results and the associated call. This fits the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights/timing). Although it announces the results release, it is not a generic 'Report Publication Announcement' (RPA) because it specifically focuses on the earnings event and call details, making ER the most precise fit among the options provided for an announcement preceding the full results.
2018-03-21 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.